Quick Answer
Alto Neuroscience, Inc. reported Long-Term Debt of $16.17 million for fiscal year 2025.
Alto Neuroscience, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $16.17M | +57.7% |
| 2024 | $10.25M | +4.0% |
| 2023 | $9.86M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $20.31M | +206.5% | +1.0% |
| June 30, 2025 | $20.12M | +159.9% | +0.9% |
| March 31, 2025 | $19.94M | +126.3% | +94.5% |
| December 31, 2024 | $10.25M | +4.0% | +54.7% |
| September 30, 2024 | $6.63M | — | -14.4% |
| June 30, 2024 | $7.74M | — | -12.2% |
| March 31, 2024 | $8.81M | — | -10.6% |
| December 31, 2023 | $9.86M | — | — |
- Alto Neuroscience, Inc. showed an increase of +57.7% in Long-Term Debt compared to the prior fiscal year.
- Over the 2023–2025 period, Alto Neuroscience, Inc.’s long-term debt has grown by 64.0% (from $9.86 million to $16.17 million).
- The most recent figure is from Alto Neuroscience, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: